JeanMarie Guenot received her MBA from the Wharton School from the University of Pennsylvania as well as a Ph.D from the University of California. She is a successful doctor who has achieved so much in the medical Industry. She majorly deals with biotechnology and Pharmaceutical areas. She is well-recognized in the construction and reconstructions of healing centers. Guenot has more than 20 years of experience in the medical industry.
Some of the companies she began and administered are SKS Ocular and SKS Ocular 1. The role of the firms is to supply medicine technologies, dry AMD, incessant release ocular drug, therapeutics for glaucoma and macular degeneration. PDL BioPhama is a company where she was the vice president of business and corporate development. She administered the management of Biogen Idec-PDL partial growth. Later on she became the firm advisor for Shanghai and Hoffmann-La Roche in Basel. JeanMarie Guenot was in charge of the Biogen Idec which has 3 divisions of autoimmune illness patients and Phase 2 Cancer.
Her great work led to her achieving an award in 2005 in Bio Business Network Initiative. PDL’s commercial and manufacturing businesses are what she was also actively associated with making her a business woman. She also took part in Portfolio Administration Committee of PDL as well as the Executive Team. Oncology, autoimmune diseases, cardiovascular diseases and neurology are other fields of medicine which she participates.
Amphivena Therapeutics is led by JeanMarie Guenot and her partners. The company was started in 2013 and is situated in San Francisco, California. The main role of the firm is to try and abolish various types of blood cancers so as to give people suffering from them a healthy life. They have a specialized enhanced therapy that combines the immune body of the victims so as to eradicate cancer lockups. They aim is to rebuild the cellular steadiness so as to achieve a strong blood flow. All of Jeanmarie Guenot’s work with Amphivena is detailed in the MarketWired article Amphivena Therapeutics Achieves Development Milestones Under Agreement With Janssen
Currently the company has initiated an antibody therapy to enhance a chance of knowing cancer symptoms. Medical experts from different organizations as well as other organizations have linked up with the company to create an enhanced network in modifying good therapy to end cancer.